Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non–Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab

A Comparison of Radiation Techniques in Patients Treated With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer

(2020) Jonathan Peng et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer

(2020) Hiroto Inoue et al.   INVESTIGATIONAL NEW DRUGS

Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer

(2020) Hyun Ae Jung et al.   LUNG CANCER

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events

(2020) Yu Miura et al.   Thoracic Cancer

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab

(2020) Narek Shaverdian et al.   Cancer Medicine

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153

(2020) David M. Waterhouse et al.   JOURNAL OF CLINICAL ONCOLOGY

Durvalumab after definitive chemoradiotherapy in locally advanced unresectable Non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)

(2020) Martin Faehling et al.   LUNG CANCER

Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study

(2020) Antoine Desilets et al.   EUROPEAN JOURNAL OF CANCER

Radiation-Induced Lung Injury

(2019) Alexander N. Hanania et al.   CHEST

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

(2019) Jhanelle E. Gray et al.   Journal of Thoracic Oncology

Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC

(2019) Steven H. Lin et al.   Journal of Thoracic Oncology

ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer

(2018) Ursula Nestle et al.   RADIOTHERAPY AND ONCOLOGY

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non–Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial

(2017) Stephen G. Chun et al.   JOURNAL OF CLINICAL ONCOLOGY

Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity

(2017) Sandra Garcia et al.   Journal of Thoracic Oncology

Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non–Small Cell Lung Cancer

(2017) Christina K. Speirs et al.   Journal of Thoracic Oncology

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2016) Suresh Senan et al.   JOURNAL OF CLINICAL ONCOLOGY

Intensity-Modulated Radiotherapy, Not 3 Dimensional Conformal, Is the Preferred Technique for Treating Locally Advanced Disease With High-Dose Radiotherapy: The Argument Against

(2015) Allan Price   SEMINARS IN RADIATION ONCOLOGY

Nondosimetric Risk Factors for Radiation-Induced Lung Toxicity

(2015) Feng-Ming (Spring) Kong et al.   SEMINARS IN RADIATION ONCOLOGY

Intensity-Modulated Radiotherapy, Not 3 Dimensional Conformal, Is the Preferred Technique for Treating Locally Advanced Lung Cancer

(2015) Joe Y. Chang   SEMINARS IN RADIATION ONCOLOGY

Combined Analysis of V20, VS5, Pulmonary Fibrosis Score on Baseline Computed Tomography, and Patient Age Improves Prediction of Severe Radiation Pneumonitis After Concurrent Chemoradiotherapy for Locally Advanced Non–Small-Cell Lung Cancer

(2014) Kayoko Tsujino et al.   Journal of Thoracic Oncology

Predicting Radiation Pneumonitis After Chemoradiation Therapy for Lung Cancer: An International Individual Patient Data Meta-analysis

(2013) David A. Palma et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: Predictors of use and association with toxicities

(2013) Shervin M. Shirvani et al.   LUNG CANCER

Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics

(2012) Y Kanda   BONE MARROW TRANSPLANTATION

Phase III Trial Comparing Docetaxel and Cisplatin Combination Chemotherapy With Mitomycin, Vindesine, and Cisplatin Combination Chemotherapy With Concurrent Thoracic Radiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: OLCSG 0007

(2010) Yoshihiko Segawa et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105

(2010) Nobuyuki Yamamoto et al.   JOURNAL OF CLINICAL ONCOLOGY

Influence of Technologic Advances on Outcomes in Patients With Unresectable, Locally Advanced Non–Small-Cell Lung Cancer Receiving Concomitant Chemoradiotherapy

(2009) Zhongxing X. Liao et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Dose–volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy

(2008) Hekun Jin et al.   RADIOTHERAPY AND ONCOLOGY